

Subject: Medical Science Liaison (MSL) Notes - Introduction of Vitaligen

Date: January 15, 2024

Provider: Dr. Kimberly Adams

Title: Endocrinologist

Institution: Metabolic Wellness Center

Summary of Key Discussion Points:

1. Introduction:

- Introduced Vitaligen as an innovative therapy for type 2 diabetes with a focus on metabolic health.
- Emphasized its unique mechanism of promoting pancreatic beta-cell regeneration.

2. Provider's Current Patient Cases:

- Dr. Adams expressed interest in exploring new options for managing patients with challenging metabolic conditions.
- Discussed specific cases where current therapies have shown limited efficacy.

3. Efficacy and Clinical Data:

- Presented recent clinical data showcasing Vitaligen's ability to reduce HbA1c levels by 1.5% on average.
- Highlighted statistically significant improvements in postprandial glucose control.

4. Safety Profile:

- Discussed the favorable safety profile of Vitaligen, with minimal reported hypoglycemic events.
- Dr. Adams inquired about potential long-term safety concerns and patient tolerability.

5. Mechanism of Action:

- Explained Vitaligen's mechanism, focusing on its role in stimulating pancreatic beta-cell proliferation.
- Dr. Adams appreciated the unique approach but sought clarification on the sustainability of beta-cell regeneration.

6. Patient Adherence and Education:

- Discussed strategies for enhancing patient adherence through simplified dosing regimens.
- Shared patient education materials emphasizing the importance of metabolic health beyond glucose control.

7. Emerging Research and Future Developments:

- Highlighted ongoing research on Vitaligen's potential in addressing insulin resistance in prediabetic individuals.
- Discussed plans for exploring combination therapies to optimize metabolic outcomes.

8. Competitive Landscape:

- Compared Vitaligen to current oral antidiabetic agents, emphasizing its potential as a disease-modifying therapy.
- Discussed the need for head-to-head trials to establish its comparative effectiveness.

9. Access and Reimbursement:

- Provided updates on access and reimbursement programs for endocrinology clinics.
- Discussed potential affordability concerns and patient assistance programs.

10. Action Items and Follow-Up:

- Dr. Adams expressed interest in receiving updates on real-world evidence studies for Vitaligen.
- Agreed upon a follow-up in three months to provide additional data and address any ongoing concerns.

11. Closing Remarks:

- Expressed gratitude for Dr. Adams's engagement and interest in advancing metabolic health.
- Reiterated commitment to ongoing collaboration and support for the Metabolic Wellness Center.